Supplementary Data from A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability

Authors:
  • ADAnna Morena D'Alise
    Anna Morena D'Alise
  • GCGabriella Cotugno
    Gabriella Cotugno
  • FLFrancesca Langone
    Francesca Langone
  • IGIrene Garzia
    Irene Garzia
  • MLMaria De Lucia
    Maria De Lucia
  • IFImma Fichera
    Imma Fichera
  • RVRosa Vitale
    Rosa Vitale
  • VBVeronica Bignone
    Veronica Bignone
  • FTFabio Giovanni Tucci
    Fabio Giovanni Tucci
  • FMFederica Mori
    Federica Mori
  • ALAdriano Leuzzi
    Adriano Leuzzi

Abstract
Fig. S1: Number of immunogenic epitopes in healthy donors vaccinated with viral antigens. Fig. S2: Size distribution of FSPs in Nous-209. Fig. S3: Detection of Nous-209 FSMs in early and late stage MSI tumors. Fig.S4: Mutation allele frequency of Nous-209 FSMs detected in tumor and healthy mucosa of 20 CRC MSI patients. Fig. S5: Schematic of Nous-209 vaccine. Fig. S6: Overview of the procedure to isolate T cells recognizing peptide Ly4_24.